© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 22, 1623-1634,
November 20, 1996
© 1996 Oxford University Press
Clinical Trials in Relapsed Prostate Cancer: Defining the Target
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center Department of Medicine, Cornell University Medical College New York, NY
Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center New York, NY
Correspondence to: Howard I. Scher, M.D., Memorial Sloan-Kettering Cancer Center, 125 York Ave., New York, NY 10021.
A re-examination of the methods of developing new treatments for patients with prostate cancer whose disease has progressed during hormone therapy is necessitated by the following: 1) the impact of prostate-specific antigen (PSA) testing on patient selection, 2) the increasing number of studies using noncytotoxic approaches, and 3) the lack of validated methods to report outcomes. PSA monitoring after primary therapy has increased the number of patients referred for therapy with a rising value in this marker or an asymptomatic change in a radionuclide bone scan as the only manifestation(s) of relapse. The development of drugs for this population of patients presents a unique challenge because the classical criterion used to assess efficacy in the phase II setting, i.e., the presence of objective changes in measurable disease sites, frequently does not apply. Since no approach has been proven to prolong survival, the highest priority must be placed on developing new therapies. Standardizing the methods for evaluating treatments is also essential so that promising strategies are pursued and inactive therapies are not developed further.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Olmos, H.-T. Arkenau, J. E. Ang, I. Ledaki, G. Attard, C. P. Carden, A. H. M. Reid, R. A'Hern, P. C. Fong, N. B. Oomen, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann. Onc., August 11, 2008; (2008) mdn544v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Halabi, N. J. Vogelzang, A. B. Kornblith, S.-S. Ou, P. W. Kantoff, N. A. Dawson, and E. J. Small Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer J. Clin. Oncol., May 20, 2008; 26(15): 2544 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Scher, M. Warren, and G. Heller The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Morris, T. Akhurst, S. M. Larson, M. Ditullio, E. Chu, K. Siedlecki, D. Verbel, G. Heller, W. K. Kelly, S. Slovin, et al. Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy Clin. Cancer Res., May 1, 2005; 11(9): 3210 - 3216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Galsky, E. J. Small, W. K. Oh, I. Chen, D. C. Smith, A. D. Colevas, L. Martone, T. Curley, A. DeLaCruz, H. I. Scher, et al. Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1439 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Smaletz, M. Galsky, H. I. Scher, A. DeLaCruz, S. F. Slovin, M. J. Morris, D. B. Solit, U. Davar, L. Schwartz, and W. K. Kelly Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration Ann. Onc., October 1, 2003; 14(10): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Wm. K. Kelly, V. M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, W. Tong, M. Klang, L. Schwartz, S. Richardson, E. Rosa, et al. Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously Clin. Cancer Res., September 1, 2003; 9(10): 3578 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Kelly, A. X. Zhu, H. Scher, T. Curley, M. Fallon, S. Slovin, L. Schwartz, S. Larson, W. Tong, B. Hartley-Asp, et al. Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2098 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Halabi, E. J. Small, P. W. Kantoff, M. W. Kattan, E. B. Kaplan, N. A. Dawson, E. G. Levine, B. A. Blumenstein, and N. J. Vogelzang Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer J. Clin. Oncol., April 1, 2003; 21(7): 1232 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Carducci, R. J. Padley, J. Breul, N. J. Vogelzang, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman, A. A. Nabulsi, R. A. Humerickhouse, M. A. Weinberg, et al. Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial J. Clin. Oncol., February 15, 2003; 21(4): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Halabi, E. J. Small, D. F. Hayes, N. J. Vogelzang, and P. W. Kantoff Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583 J. Clin. Oncol., February 1, 2003; 21(3): 490 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Do Biostatistical Approaches for Modeling Longitudinal and Event Time Data Clin. Cancer Res., August 1, 2002; 8(8): 2473 - 2474. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Verbel, G. Heller, W. K. Kelly, and H. I. Scher Quantifying the Amount of Variation in Survival Explained by Prostate-specific Antigen Clin. Cancer Res., August 1, 2002; 8(8): 2576 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher and G. Heller Picking the Winners in a Sea of Plenty Clin. Cancer Res., February 1, 2002; 8(2): 400 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Haut, J. F. Harryhill, J. Rosenstock, M. J. Warhol, and R. Vitti Progressing Prostate Carcinoma Oncologist, April 1, 2001; 6(2): 183 - 196. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Small, A. McMillan, M. Meyer, L. Chen, W. J. Slichenmyer, P. F. Lenehan, and M. Eisenberger Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival J. Clin. Oncol., March 1, 2001; 19(5): 1304 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Kelly, T. Curley, S. Slovin, G. Heller, J. McCaffrey, D. Bajorin, A. Ciolino, K. Regan, M. Schwartz, P. Kantoff, et al. Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer J. Clin. Oncol., January 1, 2001; 19(1): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Barreto, G. G. Schwartz, R. Woodruff, and S. D. Cramer 25-Hydroxyvitamin D3, the Prohormone of 1,25-Dihydroxyvitamin D3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 265 - 270. [Abstract] [Full Text]
|
|
|
|
|
|
W. K. Kelly, I. Osman, V. E. Reuter, T. Curley, W. D. W. Heston, D. M. Nanus, and H. I. Scher The Development of Biologic End Points in Patients Treated with Differentiation Agents: An Experience of Retinoids in Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 838 - 846. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. D. Figg, B. Freidlin, S. Halabi, G. Hudes, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., November 1, 1999; 17(11): 3461 - 3467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bergan, E. Reed, C. E. Myers, D. Headlee, O. Brawley, H.-K. Cho, W. D. Figg, A. Tompkins, W. M. Linehan, D. Kohler, et al. A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2366 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Graham, H. I. Scher, G.-B. Liu, S. D-J. Yeh, T. Curley, F. Daghighian, S. J. Goldsmith, and S. M. Larson Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1307 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Scher Management of Prostate Cancer After Prostatectomy: Treating the Patient, Not the PSA JAMA, May 5, 1999; 281(17): 1642 - 1645. [Full Text] [PDF]
|
|
|
|
|
|
P. Sabbatini, S. M. Larson, A. Kremer, Z.-F. Zhang, M. Sun, H. Yeung, M. Imbriaco, I. Horak, M. Conolly, C. Ding, et al. Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer J. Clin. Oncol., March 1, 1999; 17(3): 948 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Medina, R. S DiPaola, and S. Goodin Treatment of hormone-refractory prostate cancer Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 32 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 H. I. Scher, W. M. K. Kelly, Z.-F. Zhang, P. Ouyang, M. Sun, M. Schwartz, C. Ding, W. Wang, I. D. Horak, and A. B. Kremer Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 244 - 251. [Abstract] [Full Text] [PDF]
|
|